Lipodystrophic syndromes

doi:10.3969/j.issn.1006-7795.2013.02.029

Abstract

Abstract:

The lipodystrophic syndromes are a heterogeneous group of congenital or acquired disorders characterized by either complete or partial lack of adipose tissue,which may occur in conjunction with pathological accumulation of fat in other distinct regions of the body. Patients with lipodystrophy suffer from numerous metabolic complications, such as severe insulin resistance, impaired glucose tolerance, diabetes mellitus, severe hyperlipidemia, progressive liver disease, and increased metabolic rate, serum leptin concentration can be low, indicating the importance of adipose tissue as an active endocrine organ. Not only does the total amount but also the appropriate distribution of fat deposits contribute to the metabolic state. Recent genetic and molecular research has improved our understanding of the mechanisms underlying lipodystrophy. Circulating levels of hormones secreted by adipose tissue, such as leptin and adiponectin, are greatly reduced in distinct subsets of patients with lipodystrophy, rationalizing the use of such hormones or agents that increase their circulating levels, such as peroxisome proliferator-activated receptor gamma(PPARγ) agonists, in a subset of patients with lipodystrophy. Other novel therapeutic approaches, including the use of growth hormone(GH) and GH-releasing factors, are also being studied as potential additions to the therapeutic armamentarium. Insights from recent research efforts and clinical trials could potentially revolutionize the treatment of this difficult-to-treat condition.

Key words: lipodystrophic, insulin resistance, treatment

CLC Number:

R714.14⁺7

ZHAO Xiangfu, ZHUANG Xiaoming. Lipodystrophic syndromes[J]. Journal of Capital Medical University, 2013, 34(2): 315-323.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2013.02.029

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2013/V34/I2/315

References

[1] Chan J L, Oral E A. Clinical classification and treatment of congenital and acquired lipodystrophy[J]. Endocr Pract, 2010,16(2):310-323.

[2] Mallewa J E, Wilkins E, Vilar J, et al. HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options[J]. J Antimicrob Chemother, 2008,62(4):648-660.

[3] Piloya T, Bakeera-Kitaka S, Kekitiinwa A, et al. Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda: a cross sectional study[J]. J Int AIDS Soc, 2012,15(2):17427.

[4] Berardinelli W. An undiagnosed endocrinometabolic syndrome: report of 2 cases[J]. J Clin Endocrinol Metab, 1954,14(2):193-204.

[5] Seip M. Lipodystrophy and gigantism with associated endocrine manifestations. A new diencephalic syndrome?[J]. Acta Paediatr, 1959,48:555-574.

[6] Garg A, Misra A. Lipodystrophies: rare disorders causing metabolic syndrome[J]. Endocrinol Metab Clin North Am, 2004,33(2):305-331.

[7] Garg A, Wilson R, Barnes R, et al. A gene for congenital generalized lipodystrophy maps to human chromosome 9q34[J]. J Clin Endocrinol Metab, 1999,84(9):3390-3394.

[8] Magré J, Delépine M, Khallouf E, et al. Identification of the gene altered in Berard in elli-Seip congenital lipodystrophy on chromosome 11q13[J]. Nat Genet, 2001,28(4):365-370.

[9] Kim C A, Delépine M, Boutet E, et al. Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy[J]. J Clin Endocrinol Metab, 2008,93(4):1129-1134.

[10] Chandalia M, Garg A, Vuitch F, et al. Postmortem findings in congenital generalized lipodystrophy[J]. J Clin Endocrinol Metab, 1995,80(10):3077-3081.

[11] Pardini V C, Victória I M, Rocha S M, et al. Leptin levels, beta-cell function, and insulin sensitivity in families with congenital and acquired generalized lipoatropic diabetes[J]. J Clin Endocrinol Metab, 1998,83(2):503-508.

[12] Lawrence R D. Lipodystrophy and hepatomegaly, with diabetes, lipaemia, and other metabolic disturbances; a case throwing new light on the action of insulin[J]. Lancet, 1946,1(6403):724.

[13] Misra A, Garg A. Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature[J]. Medicine(Baltimore), 2003,82(2):129-146.

[14] Hübler A, Abendroth K, Keiner T, et al. Dysregulation of insulin-like growth factors in a case of generalized acquired lipoatrophic diabetes mellitus(Lawrence Syndrome) connected with autoantibodies against adipocyte membranes[J]. Exp Clin Endocrinol Diabetes, 1998,106:79.

[15] Herbst K L, Tannock L R, Deeb S S, et al. Köbberling type of familial partial lipodystrophy: an underrecognized syndrome[J]. Diabetes Care, 2003,26(6):1819-1824.

[16] Agarwal A K, Garg A. A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy[J]. J Clin Endocrinol Metab, 2002,87(1):408-411.

[17] Peters J M, Barnes R, Bennett L, et al. Localization of the gene for familial partial lipodystrophy(Dunnigan variety) to chromosome 1q21-22[J]. Nat Genet, 1998,18(3):292-295.

[18] Garg A. Acquired and inherited lipodystrophies[J]. N Engl J Med, 2004,350(12):1220-1234.

[19] Garg A. Gender differences in the prevalence of metabolic complications in familial partiallipo dystrophy(Dunnigan variety)[J]. J Clin Endocrinol Metab, 2000,85(5):1776-1782.

[20] Vantyghem M C, Vincent-Desplanques D, Defrance-Faivre F, et al. Fertility and obstetrical complications in women with LMNA-related familial partial lipodystrophy[J]. J Clin Endocrinol Metab, 2008,93(6):2223-2229.

[21] Spuler S, Kalbhenn T, Zabojszcza J, et al. Muscle and nerve pathology in Dunnigan familial partial lipodystrophy[J]. Neurology, 2007,68(9):677-683.

[22] Hegele R A, Cao H, Liu D M, et al. Sequencing of the reannotated LMNB2 gene reveals novel mutations in patients with acquired partial lipodystrophy[J]. Am J Hum Genet, 2006,79(2):383-389.

[23] George S, Rochford J J, Wolfrum C, et al. A family with severe insulin resistance and diabetes due to a mutation in AKT2[J]. Science, 2004,304(5675):1325-1328.

[24] Cao H, Alston L, Ruschman J, et al. Heterozygous CAV1 frameshift mutations(MIM 601047) in patients with atypical partial lipodystrophy and hypertriglyceridemia[J]. Lipids Health Dis, 2008, 7:3.

[25] Simha V, Agarwal A K, Oral E A, et al. Genetic and phenotypic heterogeneity in patients with mandibuloacral dysplasia-associated lipodystrophy[J]. J Clin Endocrinol Metab, 2003,88(6):2821-2824.

[26] Novelli G, Muchir A, Sangiuolo F, et al. Mandibuloacral dysplasia is caused by a mutation in LMNA-encoding lamin A/C[J]. Am J Hum Genet, 2002,71(2):426-431.

[27] Agarwal A K, Fryns J P, Auchus R J, et al. Zinc metalloproteinase, ZMPSTE24, is mutated in mandibuloacral dysplasia[J]. Hum Mol Genet, 2003,12(16):1995-2001.

[28] Jackson S N, Pinkney J, Bargiotta A, et al. A defect in the regional deposition of adipose tissue(partial lipodystrophy) is encoded by a gene at chromosome 1q[J]. Am J Hum Genet, 1998,63(2):534-540.

[29] Agarwal A K, Zhou X J, Hall R K, et al. Focal segmental glomerulosclerosis in patients with mandibuloacral dysplasia owing to ZMPSTE24 deficiency[J]. J Investig Med, 2006,54(4):208-213.

[30] Barraquer L. Pathogenesis of progressive cephalothoracic lipodystrophy: Barraquer’ s disease[J]. J Nerv Ment Dis, 1949,109(2):113-121.

[31] Peters D K, Charlesworth J A, Sissons J G, et al. Mesangiocapillary nephritis, partial lipodystrophy, and hypocomplementaemia[J]. Lancet, 1973,2(7828):535-538.

[32] Sissons J G, West R J, Fallows J, et al. The complement abnormalities of lipodystrophy[J]. N Engl J Med, 1976,294(9):461-465.

[33] Misra A, Peethambaram A, Garg A. Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature[J]. Medicine(Baltimore), 2004,83(1):18-34.

[34] Mallewa J E, Wilkins E, Vilar J, et al. HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options[J]. J Antimicrob Chemother, 2008,62(4):648-660.

[35] Villarroya F, Domingo P, Giralt M. Drug-induced lipotoxicity: lipodystrophy associated with HIV-1 infection and antiretroviral treatment[J]. Biochim Biophys Acta, 2010,1801(3):392-399.

[36] Kotler D P, Hepatitis C, human immunodeficiency virus and metabolic syndrome: interactions[J]. Liver Int, 2009,29(suppl 2):38-46.

[37] Chandra S, Mondal D, Agrawal K C. HIV-1 protease inhibitor induced oxidative stress suppresses glucose stimulated insulin release: protection with thymoquinone[J]. Exp Biol Med(maywood), 2009,234(4):442-453.

[38] Shrivastav S, Kino T, Cunningham T, et al. Human immunodeficiency virus(HIV)-1 viral protein R suppresses transcriptional activity of peroxisome proliferator-activated receptor gamma and inhibits adipocyte differentiation: implications for HIV-associated lipodystrophy[J]. Mol Endocrinol, 2008,22(2):234-247.

[39] Imamura S, Yamada M, Ikeda T. Lipodystrophia centrifugalis abdominalis infantifis[J]. Arch Dermatol, 1971,104(3):291-298.

[40] Tsiodras S, Poulia K A, Yannakoulia M, et al. Adherence to Mediterranean diet is favorably associated with metabolic parameters in HIV-positive patients with the highly active antiretroviral therapy-induced metabolic syndrome and lipodystrophy[J]. Metabolism, 2009,58(6):854-859.

[41] Gavrila A, Tsiodras S, Doweiko J, et al. Exercise and vitamin E intake are independently associated with metabolic abnormalities in human immunodeficiency virus-positive subjects: a cross-sectional study[J]. Clin Infect Dis, 2003,36(12):1593-1601.

[42] Leyes P, Martinez E, Forga Mde T. Use of diet, nutritional supplements and exercise in HIV-infected patients receiving combination antiretroviral therapies: a systematic review[J]. Antivir Ther, 2008,13(2):149-159.

[43] Hadigan C, Corcoran C, Basgoz N, et al. Metformin in the treatment of HIV lipodystrophy syndrome-A randomized controlled trial[J]. JAMA, 2000,284(4):472-477.

[44] Moreau F, Boullu-Sanchis S, Vigouroux C,et al. Efficacy of pioglitazone in familial partial lipodystrophy of the Dunnigan type: a case report[J]. Diabetes Metab, 2007,33(5):385-389.

[45] Gambineri A, Semple R K, Forlani G, et al. Monogenic polycystic ovary syndrome due to a mutation in the lamin A/C gene is sensitive to thiazolidinediones but not to metformin[J]. Eur J Endocrinol, 2008,159(3):347-353.

[46] Simha V, Rao S, Garg A. Prolonged thiazolidinedione therapy does not reverse fat loss in patients with familial partial lipodystrophy, Dunnigan variety[J]. Diabetes Obes Metab, 2008,10(12):1275-1276.

[47] Raboud J M, Diong C, Carr A, et al. A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy[J]. HIV Clin Trials, 2010,11(1):39-50.

[48] Gavrila A, Hsu W, Tsiodras S, et al. Improvement in highly active antiretroviral therapy-induced metabolic syndromeby treatment with pioglitazone but not with fenofibrate: A2×2 factorial, randomized, doubleblinded, placebo-controlled trial[J]. Clin Infect Dis, 2005,40(5):745-749.

[49] Slama L, Lanoy E, Valantin M A, et al. Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial(ANRS 113)[J]. Antivir Ther, 2008,13(1):67-76.

[50] Misra A, Garg A. Clinical features and metabolic derangements in acquired generalized lipodystrophy-Case reports and review of the literature[J]. Medicine(Baltimore), 2003,82(2):129-146.

[51] Fichtenbaum C J, Gerber J G, Rosenkranz S L, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047[J]. AIDS, 2002,16(4):569-577.

[52] Aberg J A, Rosenkranz S L, Fichtenbaum C J, et al. Pharmacokinetic interaction between nelfinavir and pravastatin in HIVseronegative volunteers: ACTG study A5108[J]. AIDS, 2006,20(5):725-729.

[53] Gerber J G, Rosenkranz S L, Fichtenbaum C J, et al. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study[J]. J Acquir Immune Defic Syndr, 2005,39(3):307-312.

[54] Rao A, D’ Amico S, Balasubramanyam A, et al. Fenofibrate is effective in treating hypertriglyceridemia associated with HIV lipodystrophy[J]. Am J Med Sci, 2004,327(6):315-318.

[55] Wu J, Song Y, Li H, et al. Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report[J]. Eur J Clin Pharmacol, 2009,65(12):1169-1174.

[56] Hadigan C, Liebau J, Torriani M, et al. Improved triglycerides and insulin sensitivity with 3 months of acipimox in human immunodeficiency virus-infected patients with hypertriglyceridemia[J]. J Clin Endocrinol Metab, 2006,91(11):4438-4444.

[57] Coll B, Aragones G, Parra S, et al. Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients[J]. AIDS, 2006,20(12):1675-1677.

[58] Wanke C, Gerrior J, Kantaros J, et al. Recombinant human growth hormone improves the fat redistribution syndrome(lipodystrophy) in patients with HIV[J]. AIDS, 1999,13(15):2099-2103.

[59] Bickel M, Zangos S, Jacobi V, et al. A randomized, open-label study to compare the effects of two different doses of recombinant human growth hormone on fat reduction and fasting metabolic parameters in HIV-1-infected patients with lipodystrophy[J]. HIV Med, 2006,7(6):397-403.

[60] Falutz J, Allas S, Kotler D, et al. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation[J]. Aids, 2005,19(12):1279-1287.

[61] Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV[J]. N Engl J Med, 2007,357(23):2359-2370.

[62] Brown T T. Approach to the human immunodeficiency virus-infected patient with lipodystrophy[J]. J Clin Endocrinol Metab, 2008,93(8):2937-2945.

[63] Coope A, Milanski M, Araújo E P, et al. AdipoR1 mediates the anorexigenic and insulin/leptin-like actions of adiponectin in the hypothalamus[J]. FEBS Lett, 2008,582(10):1471-1476.

[64] Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity[J]. Nat Med, 2001,7(8):941-946.

[65] Chong A Y, Lupsa B C, Cochran E K, et al. Efficacy of leptin therapy in the different forms of human lipodystrophy[J]. Diabetologia, 2010,53(1):27-35.

[66] Musso C, Cochran E, Javor E, et al. The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients[J]. Metabolism, 2005,54(2):255-263.